Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

Pleryon Therapeutics

HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.

Shenzhen, China, AsiaBiotech & life sciences, Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerative aesthetics)
Stage
Series ANo documented AI
Product
PilotPilots / LOIs
Funding raised
$18.6Mdisclosed
Founded
201610 years ago
Founders
3Dr, Dr…
Global score
5.0Grade CRank 39 of 151

Overview

HKUST spin-off developing polymer-based drugs for ophthalmology (AMD, dry eye), osteoarthritis and regenerative aesthetics.

Traction

Pilots / LOIs

First-in-human trial of candidate P002 (dry eye) authorized by Health Canada (ITA); no product on the market.

Market

Dry eye treatments

Dry eye is a large chronic market where existing drugs have modest efficacy and need frequent dosing; polymer-based formulations can extend residence time on the ocular surface. Buyers are ultimately payers and prescribers, but for a Series A biotech the real customer is a licensing partner (ophthalmology pharma) paying upfronts and milestones after clinical proof. Pleryon's clinical entry via Health Canada signals a North American regulatory path.

Addressable market

2025
$6.4B
2030
$7.8B
+4.1% a year

Dry eye treatments: global market from $6.4bn in 2025 to $7.8bn in 2030 (Mordor, CAGR 4.1%).

Customers

Ophthalmology pharma licensees; ophthalmologists; osteoarthritis and aesthetics companies

Who signs the cheque

Pharma business development (licensing), later payers

Geographies

  • China/Hong Kong
  • Canada
  • Global licensing

Drivers

  • Ageing populations and screen use driving dry eye
  • Demand for longer-acting formulations
  • Regenerative aesthetics growth

Headwinds

  • Binary clinical risk
  • Scattered indications dilute focus
  • Long approval timelines per market

Global dry eye treatment market from $6.4bn in 2025 to $7.8bn in 2030 (Mordor, CAGR 4.1%); Grand View: $9.2bn in 2030 (osteoarthritis and AMD not counted).

Scalability 5/10. Drugs that can be licensed worldwide, but each market requires clinical trials and marketing authorizations.

Market source: giiresearch.com

Technology

Category

Drug delivery / polymer therapeutics

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

Proprietary platforms design and control the structure of large synthetic and modified natural polymers for drug delivery and injectable biomaterials. Lead candidate P002 targets dry eye in a first-in-human trial authorised by Health Canada.

Moat

Strong if clinical data confirm: polymer-structure control know-how from HKUST (Prof. Ying Chau) and formulation IP across several indications.

Differentiation

Platform approach applicable to ophthalmology, osteoarthritis and aesthetics vs single-asset biotechs.

Integration points

  • Ophthalmic diagnostics for trial endpoints
  • Cell and gene therapy delivery
  • Licensing partners' development pipelines

Depends on

  • Clinical trial outcomes
  • Regulatory authorisations per market
  • GMP polymer manufacturing

Use of AI

No use of AI mentioned

Product in detail

Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.

Business

Model
Biotech licensing / co-development; revenue from upfronts, milestones and royalties after clinical proof.
Revenue logic
Value step-ups at each clinical readout; platform deals per indication.
Go-to-market
Out-license ophthalmology asset after FIH data; platform partnerships in aesthetics.

Next milestones

  1. P002 first-in-human safety/efficacy readout
  2. Ophthalmology licensing term sheet
  3. Series B led by a global life-science investor

Key risks

  • Clinical risk
  • Scattered indications
  • Funding divergence across sources (US$15.7M vs US$20.86M)

Opportunities

4 found in the network

Concrete moves for Pleryon Therapeutics inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 2
  • Investors 1
  • Peers 1

Co-development2

An integration or joint product

Portable corneal imaging as a dry-eye trial endpoint

Pleryon's dry-eye trial needs objective ocular-surface measures; Ocuwell's portable corneal topography device is already used by clinicians. Using OCUTOP in Pleryon's trial sites gives Pleryon richer endpoints and Ocuwell a pharma-trial use case.

35%confidence

Evidence from the records

  • “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada (ITA); no product on the market.”
  • “OCUTOP used by clinicians on first patients”
If it works
Stronger clinical data package for licensing; new revenue line for Ocuwell in clinical research.
First step
Ask Ocuwell whether OCUTOP measurements fit P002's protocol endpoints and site setup.

Polymer carriers for corneal cell therapy

StemSight develops corneal cell therapy at preclinical stage; delivery and retention of cells on the cornea is a classic bottleneck that injectable biomaterials address. Pleryon's polymer platform could become StemSight's delivery matrix.

30%confidence

Evidence from the records

  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
If it works
A material-transfer and co-development agreement; platform validation in a second ophthalmic modality.
First step
Exchange non-confidential data and propose an MTA for in-vitro compatibility tests.

Investors1

A fund whose thesis fits

US biotech investor for the North American trial path

KDT invests $0.5–5M in US biotech/deep tech from pre-seed to Series A; with the FIH trial in Canada, a North American investor strengthens the US development and licensing path. KDT co-invested in network member ZymoChem, a warm route.

20%confidence

Evidence from the records

  • “Entry into the clinic”
  • “Credible but binary biotech: speculative.”
If it works
A North American co-investor in the next round and US pharma network access.
First step
Request an intro through ZymoChem and send a P002 non-confidential deck.

Peers1

Founders solving the same problem elsewhere

Compare local-delivery regulatory playbooks

Both companies build localised, extended-release delivery platforms (BioSapien in oncology implants, Pleryon in ophthalmology). Sharing regulatory and CMC learnings on biodegradable delivery systems reduces costly missteps.

20%confidence

Evidence from the records

  • “3D-printed, biodegradable, slow-release implant”
  • “polymer-based drugs for ophthalmology (AMD, dry eye), osteoarthritis and regenerative aesthetics”
If it works
Faster regulatory planning; potential joint investor introductions.
First step
Set a founder-to-founder call on biodegradable delivery CMC and regulatory lessons.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Life-sciences and venture arm of Sands Capital ($54B+ AUM); Pulse strategy ($1.3B) backs therapeutics, diagnostics, devices and tools.

HKUST polymer therapeutics with a Health Canada-authorised first-in-human trial, $18.6M raised at Series A.

45%confidence

Evidence from the records

  • “Polymer-based therapeutics”
  • “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada”
Intro path
Zero2IPO (Pleryon investor).
First step
Pitch Pleryon's next round with trial readouts.

Korean investor with an empty profile; participated in BILIX's Series A (acute kidney injury drug).

HKUST polymer therapeutics with a first-in-human trial authorised: Asian clinical-stage biotech like BILIX.

25%confidence

Evidence from the records

  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
  • “Series A”
Intro path
BILIX founders.
First step
Ask BILIX about WeVentures' biotech mandate.

Seoul asset manager seen in BILIX's seed (kidney-injury drug); its thesis, ticket and team are not documented.

Polymer-based therapeutics with a first-in-human trial authorised: clinical-stage biotech like BILIX. China-based, so Korean investor fit is unproven.

20%confidence

Evidence from the records

  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
  • “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada”
First step
Confirm Alpenroute's cross-border biotech appetite via BILIX.

Korean pharmaceutical company making strategic biotech investments, including in BILIX (2019 strategic stake and Series A).

Polymer therapeutics (ophthalmology, osteoarthritis) with first-in-human authorisation: pharma partnering candidate.

20%confidence

Evidence from the records

  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
  • “Series A”
Intro path
BILIX (Estech portfolio)
First step
Explore licensing for Korea.

Holding that invested in BioSapien's US$5.5M pre-Series A (oncology drug delivery); profile is undocumented.

Polymer therapeutics with first-in-human authorisation: clinical-stage.

15%confidence

Evidence from the records

  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
  • “Series A”

Finnish family office investing in life sciences; joined StemSight's €2.3M seed extension in 2025.

Polymer therapeutics in ophthalmology with a first-in-human trial: ophthalmic overlap, but Series A in China.

10%confidence

Evidence from the records

  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
  • “Series A”

Korean government drug-development fund supporting Korean biotech pipelines, including a 2026 grant to BILIX.

Chinese polymer therapeutics — no Korean entity.

10%confidence

Evidence from the records

  • “South Korea”
  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerative aesthetics)”
  • “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada (ITA)”
Intro path
Founder-to-founder intro via BILIX (network portfolio company of Korea Drug Development Fund (KDDF)).
First step
Low priority.

Investment analysis

5.0C

Grade C

Rank 39 of 151

Disruption7.0/10
Business model3.0/10
Market6.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Credible but binary biotech: speculative.

Disruption

7/10

Multi-indication polymer-based drugs: new approach.

Business model

3/10

First-in-human trial authorized, no product on the market.

Market

6/10

TAM dry eye treatments ~$6.36bn (base 5), medium scalability 5/10 (0), international expansion: first-in-human trial authorized in Canada from Hong Kong (+1) → 6/10.

Risk

7/10

Lower is better

High risk: clinical risk despite $18.6M raised.

Strengths

  • Entry into the clinic
  • Significant funding

Risks

  • Clinical risk
  • Scattered indications

Funding

$18.6M, disclosed
  1. 1 avr. 2022

    Pre-Anearly RMB 100M

    not named on the website (Lapam, Efung, Kaitai, Zero2IPO according to aggregators)

  2. 18–22 août 2025 (CB Insights : 18/08 ; Caplight : 22/08)

    Series ARMB 35M (press release title; the URL mentions “5m”)

    EFung Capital (cited by CB Insights and Caplight); other historical investors: Zero2IPO, Kaitai Capital, Lapam Capital, HKUST R&D Corporation

  3. 24 juin 2026

    prizenot disclosed

    HKUST 1km & Beyond Startup Pitch Competition — biotech category champion

Amount used in the study. Pre-A ~RMB 100M + Series A RMB 35M; range $15.7M-$20.86M depending on the source.

Note. ≈US$20.86M (Caplight) or US$15.7M (another source)

2025 Series A clarified (dated 18–22 August 2025, EFung Capital named); added HKUST 1km & Beyond biotech champion title (June 2026). Total amounts still diverge (US$15.7M vs US$20.86M). No SWC link found in public sources.

Team

  • Dr Yu Yu

    Founder & CEO

    PhD, from HKUST, expertise in biomaterials/drug delivery.

  • Dr Zhexun Sun

    Cofounder & CTO

    PhD, HKUST.

  • Prof. Ying Chau

    Cofounder & CSO

    Professor at HKUST (chemical and biological engineering), specialist in therapeutic polymers.

Sources

Identification confidence
medium
Founding year: 2016
2016 (according to some sources)
  1. 1innovationhub.hk/article/pleryon-therapeutics
  2. 2caplight.com/company/pleryon
  3. 3kt.hkust.edu.hk/node/365
  4. 4app.dealroom.co/companies/pleryon_therapeutics
  5. 5cbinsights.com/company/kening-biopharmaceutical/financials
  6. 6ec.hkust.edu.hk/node/13659

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet